Thermoneutrality, Mice, and Cancer: A Heated Opinion.

Abstract:

:The 'mild' cold stress caused by standard sub-thermoneutral housing temperatures used for laboratory mice in research institutes is sufficient to significantly bias conclusions drawn from murine models of several human diseases. We review the data leading to this conclusion, discuss the implications for research and suggest ways to reduce problems in reproducibility and experimental transparency caused by this housing variable. We have found that these cool temperatures suppress endogenous immune responses, skewing tumor growth data and the severity of graft versus host disease, and also increase the therapeutic resistance of tumors. Owing to the potential for ambient temperature to affect energy homeostasis as well as adrenergic stress, both of which could contribute to biased outcomes in murine cancer models, housing temperature should be reported in all publications and considered as a potential source of variability in results between laboratories. Researchers and regulatory agencies should work together to determine whether changes in housing parameters would enhance the use of mouse models in cancer research, as well as for other diseases. Finally, for many years agencies such as the National Cancer Institute (NCI) have encouraged the development of newer and more sophisticated mouse models for cancer research, but we believe that, without an appreciation of how basic murine physiology is affected by ambient temperature, even data from these models is likely to be compromised.

journal_name

Trends Cancer

journal_title

Trends in cancer

authors

Hylander BL,Repasky EA

doi

10.1016/j.trecan.2016.03.005

subject

Has Abstract

pub_date

2016-04-01 00:00:00

pages

166-175

issue

4

eissn

2405-8033

issn

2405-8025

pii

S2405-8033(16)00054-6

journal_volume

2

pub_type

杂志文章,评审
  • Targeting Nuclear Receptors for Cancer Therapy: Premises, Promises, and Challenges.

    abstract::Nuclear receptors are a family of transcription factors localized in cell nuclei, sensing specific ligands and fine-tuning a variety of cell physiological events. They have been intensively investigated in cancer biology. With their excellent properties of druggability and actionability, nuclear receptors have demonst...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2020.11.007

    authors: Yang Z,Gimple RC,Zhou N,Zhao L,Gustafsson JÅ,Zhou S

    更新日期:2020-12-16 00:00:00

  • Exit Stage Left: A Tumor Cell's Journey from Lymph Node to Beyond.

    abstract::Even though we have known for over 250 years that cancers spread to regional lymph nodes (LNs) and distant organs, the fundamental question of which anatomical routes are taken by tumor cells has remained a mystery. Two recently published papers in Science, by Pereira et al. and Brown et al., directly address this imp...

    journal_title:Trends in cancer

    pub_type: 评论,杂志文章

    doi:10.1016/j.trecan.2018.05.007

    authors: Achen MG,Stacker SA

    更新日期:2018-08-01 00:00:00

  • The Emerging Role of ABL Kinases in Solid Tumors.

    abstract::The Abelson (ABL) tyrosine kinases were identified as drivers of leukemia in mice and humans. Emerging data has shown a role for the ABL family kinases, ABL1 and ABL2, in the progression of several solid tumors. This review will focus on recent reports of the involvement of the ABL kinases in tumor progression using m...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2015.07.004

    authors: Wang J,Pendergast AM

    更新日期:2015-10-01 00:00:00

  • The Opposing Roles of PIK3R1/p85α and PIK3R2/p85β in Cancer.

    abstract::Dysregulation of the PI3K/PTEN pathway is a frequent event in cancer, and PIK3CA and PTEN are the most commonly mutated genes after TP53. PIK3R1 is the predominant regulatory isoform of PI3K. PIK3R2 is an ubiquitous isoform that has been so far overlooked, but data from The Cancer Genome Atlas shows that increased exp...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2019.02.009

    authors: Vallejo-Díaz J,Chagoyen M,Olazabal-Morán M,González-García A,Carrera AC

    更新日期:2019-04-01 00:00:00

  • A Timeline of Immune Checkpoint Inhibitor Approvals in Small Cell Lung Cancer.

    abstract::In this commentary, we review the timeline of clinical trials and regulatory actions of approved immune checkpoint inhibitors for small cell lung cancer, discuss challenges faced by regulatory agencies, and highlight paradoxical lessons that emerge. Accelerated approvals may fail to expedite drugs to market in this se...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2020.05.014

    authors: Gill J,Cetnar JP,Prasad V

    更新日期:2020-09-01 00:00:00

  • Immunotherapeutic Transport Oncophysics: Space, Time, and Immune Activation in Cancer.

    abstract::Immuno-oncology has gained momentum thanks to the success of strategies aimed at enhancing immune-mediated antitumor response. The field of immunotherapeutic transport oncophysics investigates the physical processes that drive cancer immunotherapies. This review discusses three main aspects that determine the outcome ...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2019.11.008

    authors: Nizzero S,Shen H,Ferrari M,Corradetti B

    更新日期:2020-01-01 00:00:00

  • Lysophosphatidate Signaling: The Tumor Microenvironment's New Nemesis.

    abstract::Lysophosphatidate (LPA) is emerging as a potent mediator of cancer progression in the tumor microenvironment. Strategies for targeting LPA signaling have recently entered clinical trials for fibrosis. These therapies have potential to improve the efficacies of existing chemotherapies and radiotherapy by attenuating ch...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2017.09.004

    authors: Benesch MGK,Yang Z,Tang X,Meng G,Brindley DN

    更新日期:2017-11-01 00:00:00

  • A Molecular Take on Malignant Rhabdoid Tumors.

    abstract::The molecular basis for the clinical heterogeneity observed in patients with malignant rhabdoid tumors is unknown. Recently, two reports revealed molecular inter-tumor heterogeneity in teratoid/rhabdoid tumors (ATRTs) and extra-cranial MRTs (ecMRTs) using genomic, transcriptomic and epigenomic profiling. Distinct mole...

    journal_title:Trends in cancer

    pub_type: 评论,杂志文章

    doi:10.1016/j.trecan.2016.04.003

    authors: Tang M,Verhaak RG

    更新日期:2016-05-01 00:00:00

  • Selective Targeting of RSK Isoforms in Cancer.

    abstract::The p90 ribosomal S6 kinase family (RSK1-4) is a group of highly conserved Ser/Thr kinases that act as downstream effectors of the Ras/Raf/MEK/ERK signaling pathway. The RSKs phosphorylate a range of substrates involved in transcription, translation, cell cycle regulation, and cell survival. Although the RSKs have a h...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2017.03.004

    authors: Casalvieri KA,Matheson CJ,Backos DS,Reigan P

    更新日期:2017-04-01 00:00:00

  • Nutrient Exploitation within the Tumor-Stroma Metabolic Crosstalk.

    abstract::The tumor microenvironment has an essential role in defining tumor malignancy, since it can either promote or prevent tumor initiation and subsequent progression and metastatic dissemination. Recent studies demonstrate that highly aggressive cancer cells display a high degree of metabolic plasticity paralleled by the ...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2016.11.001

    authors: Morandi A,Giannoni E,Chiarugi P

    更新日期:2016-12-01 00:00:00

  • The Hidden Conundrum of Phosphoinositide Signaling in Cancer.

    abstract::Phosphoinositide 3-kinase (PI3K) generation of PI(3,4,5)P3 from PI(4,5)P2 and the subsequent activation of Akt and its downstream signaling cascades (e.g. mTORC1) dominates the landscape of phosphoinositide signaling axis in cancer research. However, PI(4,5)P2 is breaking its boundary as merely a substrate for PI3K an...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2016.05.009

    authors: Thapa N,Tan X,Choi S,Lambert PF,Rapraeger AC,Anderson RA

    更新日期:2016-07-01 00:00:00

  • Advanced Prostate Cancer: Treatment Advances and Future Directions.

    abstract::Prostate cancer affects one in every nine men in the USA and is the second leading cause of cancer-related death. The treatment landscape of advanced prostate cancer is changing rapidly. Multiple agents including abiraterone, enzalutamide, apalutamide, darolutamide, docetaxel, cabazitaxel, radium-223, and sipuleucel-T...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2020.04.010

    authors: Swami U,McFarland TR,Nussenzveig R,Agarwal N

    更新日期:2020-08-01 00:00:00

  • Emerging Roles of GLI-Similar Krüppel-like Zinc Finger Transcription Factors in Leukemia and Other Cancers.

    abstract::GLI-similar 1-3 (GLIS1-3), a subfamily of Krüppel-like zinc finger transcription factors, function as key regulators of several biological processes important to oncogenesis, including control of cell proliferation, differentiation, self-renewal, and epithelial-mesenchymal transition. This review provides a short over...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2019.07.005

    authors: Jetten AM

    更新日期:2019-09-01 00:00:00

  • Cancer Genomics in Clinical Context.

    abstract::Precision medicine requires appropriate application of genomics in clinical practice. In cancer, we have witnessed practice-changing examples of how genomic knowledge is translated into more tailored and effective therapies. The next opportunity is to embed cancer genomics in clinical context so that patient-centric l...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2015.07.010

    authors: Chin L,Wargo JA,Spring DJ,Kantarjian H,Futreal PA

    更新日期:2015-09-01 00:00:00

  • Emerging Players in Prostate Cancer-Bone Niche Communication.

    abstract::Patients with advanced prostate cancer (PCa) frequently develop skeletal metastases that are associated with fractures, disability, and increased mortality. Within the bone metastatic niche, mutual interactions between tumor cells and osteoblasts have been proposed as major contributors of osteotropism by PCa. Here, w...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2020.09.006

    authors: Furesi G,Rauner M,Hofbauer LC

    更新日期:2021-02-01 00:00:00

  • Assessing Novel Therapies Based on Late-Stage Efficacy: A Dangerous Concept?

    abstract::Traditionally, the efficacy of novel cancer therapies has been confirmed in patients failing regular treatment before being tested in early disease. Improved understanding of the mechanisms guiding therapeutic efficacy may challenge this dogma, suggesting novel therapies to move into early evaluation based on biologic...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2020.11.010

    authors: Lønning PE

    更新日期:2020-12-22 00:00:00

  • Fanconi Anemia Signaling and Cancer.

    abstract::The extremely high cancer incidence associated with patients suffering from a rare human genetic disease, Fanconi anemia (FA), demonstrates the importance of FA genes. Over the course of human tumor development, FA genes perform critical tumor-suppression roles. In doing so, FA provides researchers with a unique genet...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2017.10.005

    authors: Nepal M,Che R,Zhang J,Ma C,Fei P

    更新日期:2017-12-01 00:00:00

  • Targeting EMT in Cancer with Repurposed Metabolic Inhibitors.

    abstract::Epithelial-to-mesenchymal transition (EMT) determines the most lethal features of cancer, metastasis formation and chemoresistance, and therefore represents an attractive target in oncology. However, direct targeting of EMT effector molecules is, in most cases, pharmacologically challenging. Since emerging research ha...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2020.06.005

    authors: Ramesh V,Brabletz T,Ceppi P

    更新日期:2020-11-01 00:00:00

  • Turning Cold into Hot: Firing up the Tumor Microenvironment.

    abstract::Cancers develop within complex tissue environments consisting of diverse innate and adaptive immune cells, along with stromal cells, vascular networks, and many other cellular and noncellular components. The high heterogeneity within the tumor microenvironment (TME) remains a key obstacle in understanding and treating...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2020.02.022

    authors: Duan Q,Zhang H,Zheng J,Zhang L

    更新日期:2020-07-01 00:00:00

  • Exons of Leukemia Suppressor Genes: Creative Assembly Required.

    abstract::Alternative splicing (AS) has many important roles in the pathogenesis of leukemia. Recent papers suggest that one of its key aspects is exclusion of 3'-terminal exons in favor of premature termination using intronic polyadenylation signals. This process generates leukemia suppressor isoforms with truncated C termini ...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2018.10.005

    authors: Asnani M,Thomas-Tikhonenko A

    更新日期:2018-12-01 00:00:00

  • Cadherins Glycans in Cancer: Sweet Players in a Bitter Process.

    abstract::Cadherins are key components in tissue morphogenesis and architecture, contributing to the establishment of cohesive cell adhesion. Reduced cellular adhesiveness as a result of cadherin dysfunction is a defining feature of cancer. During tumor development and progression, major changes in the glycan repertoire of canc...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2016.08.003

    authors: Carvalho S,Reis CA,Pinho SS

    更新日期:2016-09-01 00:00:00

  • Transforming Biomarker Development with Exceptional Responders.

    abstract::Curative therapy for cancer patients with advanced-stage disease remains elusive. While rare outlier responses to anticancer therapies exist, barriers limit our understanding of the molecular and genetic basis of such profound, life-altering responses. Here, we describe how phenotype-to-genotype studies are elucidatin...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2017.11.004

    authors: Jonsson P,Taylor BS

    更新日期:2018-01-01 00:00:00

  • Learning from the Proteasome How To Fine-Tune Cancer Immunotherapy.

    abstract::Cancer immunotherapy has recently emerged as a forefront strategy to fight cancer. Key players in antitumor responses are CD8+ cytolytic T lymphocytes (CTLs) that can detect tumor cells that carry antigens, in other words, small peptides bound to surface major histocompatibility complex (MHC) class I molecules. The su...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2017.07.007

    authors: Vigneron N,Abi Habib J,Van den Eynde BJ

    更新日期:2017-10-01 00:00:00

  • Are Microbial Endophytes the 'Actual' Producers of Bioactive Antitumor Agents?

    abstract::For millenia, plants have been a major source of medications against human and animal diseases. In the case of anticancer agents, a significant number of current agents can trace their source back to nominally plant secondary metabolites, with examples being taxol, vinca alkaloids, camptothecin (CPT), and their modifi...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2018.08.002

    authors: Newman DJ

    更新日期:2018-10-01 00:00:00

  • Resistance to Ibrutinib in B Cell Malignancies: One Size Does Not Fit All.

    abstract::Ibrutinib resistance, as a result of coordinated rewiring of signaling networks and enforced tumor microenvironment (TME)-lymphoma interactions, drives unrestrained proliferation and disease progression. To combat resistance mechanisms, we must identify the compensatory resistance pathways and the central modulators o...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2018.01.004

    authors: Shah B,Zhao X,Silva AS,Shain KH,Tao J

    更新日期:2018-03-01 00:00:00

  • CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer.

    abstract::Cancer-associated fibroblasts (CAFs) are one of the most significant components in the tumour microenvironment (TME), where they can perform several protumourigenic functions. Several studies have recently reported that CAFs are more heterogenous and plastic than was previously thought. As such, there has been a shift...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2019.09.010

    authors: Pereira BA,Vennin C,Papanicolaou M,Chambers CR,Herrmann D,Morton JP,Cox TR,Timpson P

    更新日期:2019-11-01 00:00:00

  • ADAR and Immune Silencing in Cancer.

    abstract::The regulation of immune responses by tumors is central to their survival. By diminishing the production of interferon (IFN) and other inflammatory mediators, tumors enhance immune evasion. Responses initiated by nucleic acid sensors and triggered by dysregulated RNA transcription and cytoplasmic DNA undergo down-modu...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2019.03.004

    authors: Herbert A

    更新日期:2019-05-01 00:00:00

  • Immunity Gone Astray - NETs in Cancer.

    abstract::Neutrophil extracellular traps (NETs) have emerged as significant contributors to cancer-associated pathologies such as metastasis, thrombosis, and organ dysfunction in preclinical models. We review recent discoveries of the involvement of NETs in human cancers and suggest tumor-induced NET formation as an interesting...

    journal_title:Trends in cancer

    pub_type: 杂志文章

    doi:10.1016/j.trecan.2016.10.012

    authors: Cedervall J,Olsson AK

    更新日期:2016-11-01 00:00:00

  • Protein-Protein Interactions: Emerging Oncotargets in the RAS-ERK Pathway.

    abstract::Given the implication of aberrant RAS-extracellular signal-regulated kinase (ERK) signaling in the development of a large number of tumor types, this route is under intense scrutiny to identify new anticancer drugs. Most avenues in that direction have been primarily focused on the inhibition of the catalytic activity ...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2018.07.002

    authors: García-Gómez R,Bustelo XR,Crespo P

    更新日期:2018-09-01 00:00:00

  • Cirrhosis: A Questioned Risk Factor for Hepatocellular Carcinoma.

    abstract::The liver is one of the major metabolic organs in the body, susceptible to injury caused by various factors. In response to injury, sophisticated mechanisms are engaged to repair and regenerate the damaged liver, preventing its failure. When the damage is chronic, regeneration goes awry, impairing liver function and c...

    journal_title:Trends in cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.trecan.2020.08.005

    authors: Garrido A,Djouder N

    更新日期:2021-01-01 00:00:00